| Literature DB >> 27765282 |
Helena Florez1, Pilar Peris2, Núria Guañabens1.
Abstract
Fibrous dysplasia is a skeletal disorder that is associated with a wide spectrum of clinical manifestations, including localized asymptomatic forms and extensive severe forms with severe bone deformities and endocrinological alterations, depending on age, location, extent and associated processes. Although the treatment of choice is based on bisphosphonates, the therapeutic efficacy of these agents in the control of disease activity remains uncertain. This article reviews the current data available on the treatment of this disease as well as the preliminary data on new therapeutic approaches.Entities:
Keywords: Bisfosfonatos; Bisphosphonates; Denosumab; Displasia fibrosa; FGF-23; Fibrous dysplasia; McCune-Albright syndrome; Síndrome de McCune-Albright
Mesh:
Substances:
Year: 2016 PMID: 27765282 DOI: 10.1016/j.medcli.2016.07.030
Source DB: PubMed Journal: Med Clin (Barc) ISSN: 0025-7753 Impact factor: 1.725